1 Department of Scienze Biochimiche, University of Florence, Florence, Italy
2 Clinica Medica e Cardiologia, University of Florence, Florence, Italy
3 Institute of Thoracic and Cardiovascular Surgery, University of Siena, Siena, Italy
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
In patients with diabetes and abnormal glucose tolerance, left ventricular hypertrophy is often detectable (1,2) and diastolic dysfunction is highly prevalent (3). Diabetic cardiomyopathy, characterized by both myocyte hypertrophy and enhanced collagen deposition (4), is almost invariably followed by the transition into a dilated form with depressed contractile behavior and heart failure irrespective of coronary heart disease and hypertension (4,5).
A direct link was found among glucose, angiotensin (Ang) II, reactive oxygen species (ROS) generation, and the transmission of death signaling in rat myocytes (p38 mitogen-activated protein kinase [MAPK]). Indeed, the glycosylation of O-linked N-acetylglucosamine may activate p53 in cardiomyocytes, thus enhancing angiotensinogen (AGTN) transcription and Ang II formation (6), which is finally responsible for the activation of death-related intracellular signaling pathways (4,6). In these experimental studies, hyperglycemia-induced Ang II formation failed to activate extracellular signalrelated kinase (ERK)-1/2 (6), a MAPK playing a well-accepted role in the hypertrophic response of cardiomyocytes (7,8), so that the possible relationship between glucose and Ang II in diabetic myocyte hypertrophy remains elusive.
In other cell types, the signaling cascade linking the activation of the nuclear transcriptional changes and cell growth to Ang II type I (ATI) receptor stimulation was found to include the phosphorylation of Janus-activated kinase (JAK)-2, a soluble tyrosine kinase (9) also involved in the transmission of the inflammatory processes (10). Ang IImediated JAK2 activation in vitro was also found to critically require ROS generation via the membrane-bound NADPH oxidase system (10). However, the capability of Ang II to induce JAK2 phosphorylation in cardiomyocytes was observed only in neonatal rat cells (1113), whereas no information is available in adult ventricular myocytes.
In rat mesangial cells, Ang IImediated JAK2 activation in vitro was found to be enhanced in the presence of high glucose concentration (14), and high glucose is known to enhance both ROS generation (15) and Ang II formation (6). However, although there have been several studies showing that high glucose potentiates local renin-angiotensin system (RAS) in cardiomyocytes of experimental animals, no study was conducted in human ventricular myocytes, and the mechanism for activated local RAS in that condition remains elusive. It has been shown that chymase rather than ACE is a major determinant for local Ang II generation in the canine (16), baboon (17), and human (18) hearts. These observations tend to minimize the role of ACE in the conversion of Ang I to Ang II in human heart failure. However, opposite results have also been reported (19), and ACE, rather than chymase, was found to be overexpressed in human failing hearts (20). One of the problems with these findings is that little attention has been given to myocytes even though the entire myocardium or the properties of the interstitial fluid have been analyzed (1620).
In this article, the hypothesis was raised that glucose and Ang II might interact to enhance NADPH oxidase activation and JAK2 phosphorylation in human ventricular myocytes. In particular, we investigated whether high glucose may enhance JAK2 activation in human myocytes, the role played by Ang II, and the pathways involved in high glucoseenhanced Ang II formation in failing myocytes.
![]() |
RESEARCH DESIGN AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The protocol of this study complies with the principles of the Helsinki Declaration and was approved by our institution (University of Florence). All patients gave their informed written consent to participate and to have their hearts used for the study.
Myocyte isolation.
Myocytes were isolated with the enzymatic digestion method as previously described (20). Briefly, a coronary artery branch was cannulated and perfused for 10 min with a calcium-free buffer (blood washout) and then with collagenase (Worthington-type II, 100 units/ml, 20 ml/min). The collagenase-perfused tissue was then minced and shaken in a resuspension buffer (HEPES-MEM buffer supplemented with bovine serum albumin 0.5%, 0.3 mmol/l CaCl2, and 10 mmol/l taurine). Myocytes were then collected and enriched by centrifugation for 4 min at 35g. Cells were then suspended in isotonic Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden) at a final concentration of 41% and centrifuged for 10 min at 34g. Pellets were washed and smears were made (Fig. 1). Rod-shaped, trypan blueexcluding cells constituted nearly 80% of all myocytes. Nonmyocytes accounted for <2% of the cells (20).
|
RT-PCR.
To document the presence of transcripts for the two Ang receptor subtypes, for other local RAS components, and for chymase in human ventricular nonfailing and failing myocytes, total mRNA was extracted with TRIzol reagent (BRL-Life Technologies), as indicated by the manufacturer, and reverse-transcribed using oligo dT as previously reported (20). The resulting cDNA was amplified using specific primers for AGTN (20), ACE (21), AT1 receptor (22), AT2 receptor (22), chymase (18), and GAPDH used as internal standard (20). To ensure that different amounts of PCRs on myocardial biopsies were not due to markedly different mRNA starting concentrations, PCR analysis for GAPDH was performed on serial twofold dilutions of cDNA for each sample. The last dilution giving a positive reaction for GAPDH was used to equalize the amount of cDNA used in each PCR.
PCRs were performed in a DNA Thermal Cycler (Perkin Elmer Cetus), band densities were analyzed using a computer image densitometer (Qwin; Leica), and the densitometric ratio to GAPDH was calculated for each transcript (20).
Incubation of myocytes with high glucose or Ang II.
Freshly isolated myocytes (105 cell/ml) from both nonfailing and dilated cardiomyopathy hearts were suspended in Dulbeccos minimal essential medium (DMEM) (pH 7.4) and in the absence of insulin. After 30 min, the medium was changed with DMEM containing 5.5 mmol/l (normal glucose) or 25 mmol/l glucose (high glucose) corresponding to plasma levels of 100 and 450 mg/dl, respectively. Hyperosmolarity was corrected by decreasing salts (final osmolarity 322 mOsm/kg), and acidosis was corrected by adding 20 mmol/l HEPES. In separate experiments, the effect of osmolarity was checked by adding 19.5 mmol/l of mannitol or glucose to normal glucose buffer. The medium was supplemented with 100 units/ml penicillin G and 0.1 mg/ml streptomycin. The cells were incubated under an atmosphere of 95% air plus 5% CO2 at 37°C for 2, 6, and 12 h.
To investigate the relative role of Ang II receptor subtypes and the involvement of the RAS in high glucoseinduced JAK2 activation, myocytes were preincubated with selective AT1 (1 µmol/l valsartan) or AT2 (1 µmol/l PD123319) receptor antagonists and with an ACE inhibitor (100 nmol/l ramipril).
In addition, to try to characterize ROS induced by Ang II, we performed experiments in the presence of a cell-permeable superoxide anion scavenger (100 µmol/l tiron), a flavoprotein inhibitor (100 µmol/l diphenyleneiodonium [DPI]), an inhibitor of NADPH oxidase system (10 µmol/l apocynin), and an inhibitor of mitochondrial ROS production (5 µmol/l rotenone).
These compounds were added 30 min before glucose. Preliminary experiments revealed that the incubation of myocytes with tiron, diphenyleneiodonium (DPI), apocynin, and rotenone in the absence of Ang II and in normal glucose did not cause any nonspecific effect on JAK2 phosphorylation status.
To investigate whether glucose may affect Ang II signaling, myocytes were then coincubated with Ang II (100 nmol/l) in the presence of AT1 or AT2 receptor antagonists, tiron, DPI, apocynin, and rotenone at the concentrations reported above, with normal glucose or high glucose. Myocytes were then separated and frozen at 80°C.
Western blot.
Myocytes were then suspended in ice-cold lysis buffer (10 nmol/l Tris-HCl, 20 mmol/l NaCl, 1 mmol/l sodium orthovanadate, 10 mmol/l sodium pyrophosphate, 10 mmol/l okadaic acid, 2 mmol/l EGTA, 2 mmol/l dithiotreitol, and 1 mmol/l phenylmethylsulfonyl fluoride, pH 7.4). Lysates were kept on ice, sonicated four times for 5 s, and centrifuged for 10 min at 13,000g. Protein concentration in the supernatant fraction was assessed by the Bradfords method.
Samples (25 µg proteins) were then separated by 8% SDS-PAGE. The gel was then transferred to nitrocellulose membrane (Hybond-ECL, Amersham Biosciences) and blocked by 1-h incubation at room temperature in TTBS (Tris-buffered saline with 0.05% Tween 20, pH 7.4) plus 5% skimmed milk powder. The nitrocellulose membrane was incubated overnight at 4°C with anti-human phospho-JAK2 (Upstate) or anti-human JAK2 antibodies (Santa Cruz). Then the nitrocellulose membrane was washed twice for 10 min with TTBS and incubated for 30 min with goat anti-rabbit IgG horseradish peroxidase conjugate antibody (Amerham Biosciences). After extensive washing, the bound antibody was visualized by a chemiluminescent detection system.
Positive control was performed by stimulating nonfailing myocytes with interleukin 6 (10 ng/ml). Negative controls were obtained both in the presence of competing peptide (Santa Cruz SC16566P) and with no first-antibody control lane.
Data analysis.
Data are reported as means ± SD. Autoradiograms were analyzed by an image analyzer. All statistical comparisons were made using Students t test for paired data and ANOVA. Significance was P < 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The lack of response observed in the presence of mannitol and the comparable effects of high glucose on JAK2 phosphorylation at normal and high final osmolarity (Fig. 3) indicate that the effect of glucose is independent of either reduction of salt content or osmolarity changes.
|
|
|
|
|
The different response between failing and nonfailing myocytes was not due to different Ang II surface receptor populations because Ang II receptor binding on ventricular myocytes was not significantly different from nonfailing myocytes (Table 2). RT-PCR studies confirmed at the mRNA level the results obtained in binding studies for AT1 and AT2 receptor subtypes (Fig. 8). Conversely, a significant increase in both the AGTN and ACE mRNA ratios to GAPDH (4.4 ± 0.6fold and 2.5 ± 0.4fold vs. nonfailing cells, respectively) was found in failing cardiomyocytes.
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
High glucose enhances Ang IIinduced JAK2 activation in nonfailing myocytes.
Clinical studies have shown that in diabetic patients the inhibition of RAS may offer additional specific vascular and renal protection, beyond the lowering of blood pressure (23). A close link was reported to exist between high glucose, Ang II myocyte formation, and activation of intracellular pathway of death signaling (6). In particular, in rat cardiomyocytes high glucose induces enzymatic glycosylation of p53, which in turn activates Ang II production leading to p38 MAPK phosphorylation (6). In humans, diabetic cardiomyopathy is also characterized by myocyte hypertrophy (4). However, experimental studies in rats indicate that glucose induces only the phosphorylation of Jun NH2-terminal kinase (JNK) (6), which plays a minor role in myocyte hypertrophy (24), whereas the MAPK pathway mainly related with myocyte hypertrophy (ERK1/2) (7,8) remained unaffected (6). No information was available regarding the response of a different intracellular pathway activated by JAK2 phosphorylation, which is known to play a relevant role in myocyte hypertrophy (25,26). Therefore, the observation that high glucose enhances Ang IImediated JAK2 phosphorylation in nonfailing myocytes extend previous results revealing the possible involvement in diabetic cardiomyopathy of an intracellular pathway distinct from MAPK.
The second observation is that at variance with that reported in other cell types (10) and in neonatal myocytes (1113), the stimulation of AT1 receptor subtype does not activate JAK2 in nonfailing human adult ventricular cardiomyocytes. The capability of the AT1 receptor to bind to the intracellular tyrosine kinase JAK2 was demonstrated and the AT1 receptor is known to contain a YIPP (tyrosine-isoleucine-proline-proline amino acids 319322) motif in the cytoplasmic tail that may recruit JAK2 (27). However, although the biochemical structure creates a signaling complex mechanistically similar to that observed with growth factor and cytokine receptors, in our human adult myocytes, Ang II evoked a JAK2 response only in the presence of high glucose. Thus, a discrepancy exists between the response of neonatal cells and the close control over AT1-mediated JAK2 activation, which seems to operate in human adult ventricular myocytes. The different response might be related with the higher activity of intracellular phosphatase in adult than in neonatal cells (28). In the present study we did not measure the response of intracellular phosphatase to Ang II stimulation. However, phosphatase likely plays a minor role in Ang IIinduced JAK2 response in the presence of high glucose because, although AT2 receptor subtype was reported to enhance phosphatase activity (29,30), the AT2 blockade failed to enhance JAK2 phosphorylation. A second possible relevant regulator of JAK2 response is represented by ROS. The capability of ROS to mediate JAK2 phosphorylation was observed in other cell types, such as fibroblasts and A-431 cells (31) and in aortic smooth muscle cells (10,32). In the present study the critical role of ROS also in human cardiomyocytes was demonstrated by the effects of tiron (a cell-permeable O2 scavenger) and DPI (a nonspecific flavoprotein inhibitor). In the heart, NADPH oxidase is considered to be the main source of Ang IIinduced O2 production (10,33), but other possible sources of ROS in diabetes are known to exist. In particular, in different cell types high glucose was reported to induce O2 generation not only via NADPH oxidase but also by mitochondrial oxidase (34). A possible participation of both NADPH and mitochondrial source seems to exist because the same inhibitory response was obtained in the presence of both apocynin, which blocks the association of p47phox cytosolic subunit with the NADPH oxidase membrane (35), and rotenone, which inhibits NADH dehydrogenase in mitochondrial complex I (36).
The time course of JAK2 activation by Ang II in the presence of high glucose appears to be a relatively late event when compared with previous studies performed in different cell types (14,37). However, in contrast with the quoted studies in which cells were preincubated in high glucose or normal glucose for long durations (up to 24 h) before the addition of Ang II, in our study the time course started after the addition of both high glucose and Ang II. Thus, it is conceivable that the late response of JAK2 phosphorylation may be due to the time required by glucose to increase ROS generation.
Therefore, these experiments, although they do not solve the question of whether in nonfailing human myocytes the capability of Ang II to induce ROS generation is limited or whether the ROS generated are promptly inactivated, clearly indicate that high glucose may allow Ang II to reach a threshold level of ROS necessary to activate JAK2.
The effects of Ang II in the presence of high glucose might also have clinical relevance owing to the early increase in Ang II cardiac generation in response to hemodynamic overload (38) or in asymptomatic patients in a very early phase of heart failure (20). The effects of a persistent increase of cardiac Ang II generation on growth factors production and collagen deposition (39) might thus be amplified in diabetic subjects. In particular, the close relationship between mechanical forces and cardiac Ang II generation stress the importance of reaching a low target of blood pressure in diabetic individuals.
Role of Ang II in glucose-induced JAK2 activation in failing myocytes.
The present results show that failing myocytes, unlike those from nonfailing cells, respond to high glucose with JAK2 activation even in the absence of exogenous Ang II. The capability of AT1 antagonism to inhibit high glucoseinduced JAK2 activation agrees with previous studies performed in rat cardiomyocytes that demonstrated the capability of glucose to induce Ang II formation (6). An important aspect revealed by the present study is that the same response is antagonized also by an ACE inhibitor. This result strongly suggests that Ang IIactivating JAK2 is newly synthesized by myocytes and that ACE is a relevant source of Ang II formation in human failing myocytes. Other studies indicated that chymase rather than ACE is a major determinant for local Ang II generation in cardiac tissue (18). However, the expression of mRNA for ACE rather than chymase was reported to be increased in the myocardium of patients with heart failure (20). The limit of all these studies is mainly related to the absence of any information regarding isolated cardiomyocytes. The only study investigating this aspect was performed in animals (dogs) with experimental heart failure (pacing) and reported an increased expression of mRNAs for the RAS components regulating Ang II formation (angiotensinogen, renin, and ACE) in failing cardiomyoctes without any changes in chymase gene expression (40). The present study reveals for the first time that human ventricular cardiomyocytes express mRNAs for all the components of the RAS and that the progression to heart failure is characterized by marked overexpression of angiotensinogen and ACE with no changes in the expression of chymase. Although these results do not exclude that both enzymes may be involved in Ang II formation in failing myocytes, the comparable effect of AT1 antagonist and ACE inhibition on JAK2 phosphorylation suggests that in this condition ACE may represent the major pathway for myocyte Ang II formation.
Experiments performed with the different ROS inhibitors indicate that also in failing myocytes ROS generation mediates high glucoseinduced JAK2 phosphorylation. Therefore, also in failing adult myocytes, ROS generation is a determinant for Ang II to induce JAK2 activation. The enhanced ROS generation might be particularly relevant in human failing hearts where NADPH oxidase, which is recognized as a major source of ROS, is known to be overactivated (41).
The second relevant difference observed in failing myocytes is that, at variance with nonfailing cells, Ang II induces JAK2 activation also in the presence of normal glucose concentration. The two Ang receptor subtypes mediate opposite intracellular effects in cardiomyocytes because AT1 was reported to activate NADPH oxidase (4143), JAK2 (9,10,27), and MAPK phosphorylation (44), whereas AT2 was shown to antagonize AT1 effects by activating MAPK-1 phosphatase (29,30). The different pattern of response between failing and nonfailing cells appears undue to a different expression of Ang II receptors, because failing and nonfailing cells share the same absolute number and relative AT1toAT2 receptor ratio at both protein and mRNA levels. On the other hand, the different JAK2 response to Ang II stimulation is unlikely due to the participation of a different source of ROS. Antioxidant enzymes are decreased in the failing heart (33,41), so that it cannot be excluded that high glucoseinduced superoxide generation may be increased in myocytes isolated from failing hearts.
In conclusion, although we did not investigate the activation of different STATs (signal transducer activators of transcription) following JAK2 phosphorylation in either nonfailing or failing hearts, our results may have relevant clinical implications. The capability of high glucose to allow Ang II to activate an important pathway for myocyte hypertrophy in nonfailing hearts may offer a reason for the importance of the strict blood pressure control in diabetic individuals. On the other hand, the capability of glucose to directly enhance Ang II release in failing hearts and to activate a pathway that is also related to intracellular signaling of inflammation indicates that high glucose can directly amplify diabetic cardiac complications.
Address correspondence and reprint requests to Prof. Pietro Amedeo Modesti, MD, PhD, Clinica Medica e Cardiologia, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. E-mail: pamodesti{at}unifi.it
Received for publication April 4, 2004 and accepted in revised form November 11, 2004
AGTN, angiotensinogen; Ang, angiotensin; AT1, Ang II type I; AT2, Ang II type II; DMEM, Dulbeccos minimal essential medium; DPI, diphenyleneiodonium; ERk, extracellular signalrelated kinase; JAK, Janus-activated kinase; MAPK, mitogen-activated protein kinase; RAS, renin-angiotensin system; ROS, reactive oxygen species
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum | DOC News |